Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

WGC ties up with IIM-A to set up research centre

The idea is to develop insights into how the significant stocks of gold in India can be used to advance growth, jobs, social inclusion and

Government expects chemical industry to grow by 15%

Industry currently accounts for 2.51% of India's GDP

Today's picks- 26 November 2014

Nifty, Bank Nifty,ITC, Jindal Steel & Power Ltd & Bharti Airtel

Sensex edges up on hopes of rate cut

The BSE Sensex and Nifty edged up on Wednesday, gaining for a fourth session in five, led by blue-chips on continued hopes the central bank ...

RBI to conduct open market operations of bonds worth Rs 12,000 cr

Due to this government bond yields are seen rising tomorrow

Back to Top